Durvalumab Overview
Introduction of Durvalumab
Durvalumab is a human IgG1κ monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules. It was developed by Medimmune/AstraZeneca, and is approved by Food and Drug Administration (FDA) and Health Canada with the trade name Imfinzi for the treatment of patients with locally advanced or metastatic urothelial carcinoma and locally advanced unresectable non-small cell lung cancer.
Mechanism of Action of Durvalumab
Durvalumab blocks PD-L1 binding to PD-1 and CD80, which prevents a Src homology 2 domain-containing protein tyrosine phosphatase (SHP2)-mediated co-inhibitory signal, allowing the neoepitope expressed by major histocompatibility complex (MHC)-I to act as signal in stimulating an immune response, leading to the release of perforins and granzymes, theoretically leading to destruction of the tumor cell.
Fig.1 Mechanism of Action of Durvalumab
Clinical Projects of Durvalumab*
| NCT ID | Status | Conditions | Lead Sponsor | Update Time |
| NCT03022500 | Recruiting | Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC | Seoul National University Hospital | January 16, 2017 |
| NCT02658214 | Recruiting | Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Esophagogastric Junction Neoplasms, Carcinoma, Pancreatic Ductal, Esophageal Squamous Cell Carcinoma | AstraZeneca | January 18, 2016 |
| NCT03308396 | Recruiting | Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma | Ajjai Alva, MD | October 12, 2017 |
| NCT03245541 | Recruiting | Neoplasms Pancreas | Cedars-Sinai Medical Center | August 10, 2017 |
| NCT03038477 | Recruiting | Pancreatic Cancer | University of Colorado, Denver | January 31, 2017 |
| NCT02639065 | Recruiting | Esophageal Cancer | Shadia Jalal, MD | December 24, 2015 |
| NCT02891161 | Recruiting | Urothelial Cancer | Monika Joshi, MD | September 7, 2016 |
| NCT02962063 | Recruiting | Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Memorial Sloan Kettering Cancer Center | November 11, 2016 |
| NCT02802098 | Recruiting | Metastatic Breast Cancer, Bevacizumab-alone Maintenance Treatment Progression | Centro Nacional de Investigaciones Oncologicas CARLOS III | June 16, 2016 |
| NCT03084471 | Recruiting | Advanced Solid Malignancies | AstraZeneca | March 21, 2017 |
| NCT03234153 | Not yet recruiting | Muscle-invasive Bladder Cancer | University Hospital Inselspital, Berne | July 31, 2017 |
| NCT03102047 | Recruiting | Rectal Cancer | NSABP Foundation Inc | April 5, 2017 |
| NCT03081923 | Recruiting | Germ Cell Tumor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | March 16, 2017 |
| NCT03430895 | Recruiting | Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Metastatic Bladder Cancer | Memorial Sloan Kettering Cancer Center | February 13, 2018 |
| NCT03202758 | Recruiting | Colorectal Cancer Metastatic | Centre Georges Francois Leclerc | June 29, 2017 |
| NCT03496519 | Not yet recruiting | Solid Tumor, Adult | University of Colorado, Denver | April 12, 2018 |
| NCT03174275 | Recruiting | Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer | UNC Lineberger Comprehensive Cancer Center | June 2, 2017 |
| NCT02793466 | Recruiting | Solid Tumor, Lymphoma, Central Nervous System Tumors | Children's Hospital Los Angeles | June 8, 2016 |
| NCT02725489 | Enrolling by invitation | Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer | Mary Crowley Medical Research Center | April 1, 2016 |
| NCT02963831 | Recruiting | ColoRectal Cancer,Platinum-resistant Ovarian Cancer | Ludwig Institute for Cancer Research | November 15, 2016 |
| NCT03428126 | Recruiting | Malignant Neoplasms of Digestive Organs，Colorectal Cancer, Colon Cancer | M.D. Anderson Cancer Center | February 9, 2018 |
| NCT03015129 | Recruiting | Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent, Endometrial Carcinoma Recurrent | Memorial Sloan Kettering Cancer Center | January 9, 2017 |
| NCT03439085 | Not yet recruiting | Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Human Papilloma Virus | M.D. Anderson Cancer Center | February 20, 2018 |
| NCT03094286 | Recruiting | HIV, Cancer | Spanish Lung Cancer Group | March 29, 2017 |
| NCT02556463 | Recruiting | Solid Tumors, CTCL, Cancer | MedImmune LLC | September 22, 2015 |
| NCT03122509 | Recruiting | Metastatic Colorectal Cancer | Memorial Sloan Kettering Cancer Center | April 20, 2017 |
| NCT03430518 | Not yet recruiting | HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer | Amy Tiersten | February 13, 2018 |
| NCT02087423 | Active, not recruiting | Non-Small Cell Lung Cancer | AstraZeneca | March 14, 2014 |
| NCT03003962 | Recruiting | Non Small Cell Lung Carcinoma NSCLC | AstraZeneca | December 28, 2016 |
| NCT03116529 | Recruiting | Soft Tissue Sarcoma | University of Maryland | April 17, 2017 |
| NCT03446547 | Recruiting | NSCLC, Stage I | Vastra Gotaland Region | February 27, 2018 |
| NCT03164616 | Recruiting | Non Small Cell Lung Cancer NSCLC | AstraZeneca | May 23, 2017 |
| NCT03421353 | Recruiting | Carcinoma, Non-small-cell Lung, Neoplasms, Carcinoma, Bronchogenic, Bronchial Neoplasms, Thoracic Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms | AstraZeneca | February 5, 2018 |
| NCT02901548 | Recruiting | Carcinoma in Situ of Bladder, Bladder Cancer | H. Lee Moffitt Cancer Center and Research Institute | September 15, 2016 |
| NCT03345810 | Recruiting | arcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Lung Adenocarcinoma Metastatic, Large Cell Lung Carcinoma Metastatic | AIO-Studien-gGmbH | November 17, 2017 |
| NCT02805660 | Recruiting | Advanced Cancer | Mirati Therapeutics Inc. | June 20, 2016 |
| NCT03132467 | Recruiting | Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer | M.D. Anderson Cancer Center | April 27, 2017 |
| NCT02726997 | Recruiting | Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | M.D. Anderson Cancer Center | April 4, 2016 |
| NCT03007407 | Recruiting | Colorectal Cancer Metastatic | NSABP Foundation Inc | January 2, 2017 |
| NCT03406650 | Recruiting | Urothelial Cancer | Swiss Group for Clinical Cancer Research | January 23, 2018 |
| NCT03452332 | Not yet recruiting | Malignant Neoplasms of Female Genital Organs, Cervical Cancer, Vaginal Cancer, Vulvar Cancer | M.D. Anderson Cancer Center | March 2, 2018 |
| NCT02898116 | Active, not recruiting | Non-small Cell Lung Cancer,Carcinoma, NSCLC | Ludwig Institute for Cancer Research | September 13, 2016 |
| NCT03277482 | Recruiting | Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer, Metastatic Vulvar Cancer, Metastatic Endometrial Cancer, Recurrent Cervical Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Endometrial Cancer | Dana-Farber Cancer Institute | September 11, 2017 |
| NCT02685826 | Active, not recruiting | Multiple Myeloma | Celgene | February 19, 2016 |
| NCT02740985 | Recruiting | Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC) | AstraZeneca | April 18, 2016 |
| NCT03003520 | Active, not recruiting | Lymphoma, Large B-Cell, Diffuse | Celgene | December 28, 2016 |
| NCT02879162 | Recruiting | Advanced Rare Tumours | Canadian Cancer Trials Group | August 25, 2016 |
| NCT02628132 | Recruiting | Breast Cancer | King Faisal Specialist Hospital & Research Center | December 11, 2015 |
| NCT03435107 | Recruiting | Metastatic Colorectal Cancer | Asan Medical Center | February 15, 2018 |
| NCT02754856 | Recruiting | Colorectal Cancer, Liver Metastases | M.D. Anderson Cancer Center | April 28, 2016 |
| NCT02643303 | Recruiting | Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer | Ludwig Institute for Cancer Research | December 31, 2015 |
| NCT03051906 | Not yet recruiting | Head and Neck Neoplasms | Azienda Ospedaliero-Universitaria Careggi | February 14, 2017 |
| NCT02733042 | Active, not recruiting | Lymphoma,Leukemia, Lymphocytic, Chronic, B-Cell | Celgene | April 11, 2016 |
| NCT03450967 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma | Samsung Medical Center | March 1, 2018 |
| NCT02520453 | Recruiting | Esophageal Cancer | Samsung Medical Center | August 11, 2015 |
| NCT03419559 | Recruiting | Non Small Cell Lung Cancer | Iovance Biotherapeutics, Inc. | February 2, 2018 |
| NCT03162224 | Recruiting | Head and Neck Cance, Human Papilloma Virus | MedImmune LLC | May 22, 2017 |
| NCT03472274 | Not yet recruiting | Bladder Cancer | Fundacion CRIS de Investigación para Vencer el Cáncer | March 21, 2018 |
| NCT02807454 | Active, not recruiting | Multiple Myeloma | Celgene | June 21, 2016 |
| NCT02812420 | Recruiting | Malignant Neoplasms of Urinary Tract | M.D. Anderson Cancer Center | June 24, 2016 |
| NCT03522584 | Not yet recruiting | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | University of Washington | May 11, 2018 |
| NCT03482102 | Not yet recruiting | Hepatocellular Carcinoma, Biliary Tract Cancer | Massachusetts General Hospital | March 29, 2018 |
| NCT02616640 | Active, not recruiting | Multiple Myeloma | Celgene | November 30, 2015 |
| NCT03490760 | Not yet recruiting | Adenocarcinoma of the Pancreas | Baptist Health South Florida | April 6, 2018 |
| NCT02788773 | Recruiting | Prostate Cancer | Canadian Cancer Trials Group | June 2, 2016 |
| NCT02671435 | Recruiting | Advanced Solid Tumors | MedImmune LLC | February 2, 2016 |
| NCT02938793 | Recruiting | Cancer, Rare Disease | Greenville Health System | October 19, 2016 |
| NCT03373760 | Recruiting | Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Southwest Oncology Group | December 14, 2017 |
| NCT02453282 | Active, not recruiting | Non-Small-Cell Lung Carcinoma NSCLC | AstraZeneca | May 25, 2015 |
| NCT03204812 | Recruiting | Castration-resistant Prostate Cancer | M.D. Anderson Cancer Center | July 2, 2017 |
| NCT02649686 | Active, not recruiting | Metastatic Breast Cancer | Canadian Cancer Trials Group | January 7, 2016 |
| NCT03317457 | Recruiting | Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma | AIO-Studien-gGmbH | October 23, 2017 |
| NCT03085849 | Recruiting | Extensive-stage Small Cell Lung Cancer | Catherine Shu | March 21, 2017 |
| NCT02904954 | Recruiting | Carcinoma, Non-Small-Cell Lung | Weill Medical College of Cornell University | September 19, 2016 |
| NCT03046862 | Recruiting | Biliary Tract Neoplasms | Seoul National University Hospital | February 8, 2017 |
| NCT02899195 | Recruiting | Mesothelioma, Pleural Mesothelioma | PrECOG, LLC. | September 14, 2016 |
| NCT03376659 | Not yet recruiting | Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Georgetown University | December 18, 2017 |
| NCT02775903 | Active, not recruiting | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Celgene | May 18, 2016 |
| NCT03057106 | Recruiting | Lung Cancer Metastatic | Canadian Cancer Trials Group | February 17, 2017 |
| NCT02250326 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | Celgene | September 26, 2014 |
| NCT02827838 | Recruiting | Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma | Wake Forest University Health Sciences | July 11, 2016 |
| NCT03095274 | Recruiting | Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung | Grupo Espanol de Tumores Neuroendocrinos | March 29, 2017 |
| NCT03005002 | Recruiting | Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer | City of Hope Medical Center | December 29, 2016 |
| NCT02997332 | Recruiting | Head and Neck Cancers | Gustave Roussy, Cancer Campus, Grand Paris | December 20, 2016 |
| NCT03473574 | Not yet recruiting | Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable, Gallbladder Carcinoma Non-Resectable | AIO-Studien-gGmbH | March 22, 2018 |
| NCT02669914 | Active, not recruiting | Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast, Cancer of the Breast, Gastroesophageal Cancer, Pancreatic Cancer, Cancer of the Pancreas, Colorectal Cancer, Colorectal Carcinoma, Renal Cancer, Kidney Cancer, Cancer of the Kidney, Cancer of Kidney, Ovarian Cancer, Ovary Cancer, Cancer of the Ovary, Cancer of Ovary | Washington University School of Medicine | February 1, 2016 |
| NCT03054532 | Not yet recruiting | LYMPHOMA | Singapore General Hospital | February 15, 2017 |
| NCT02811497 | Recruiting | Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II, Estrogen Receptor Positive and HER2 Negative Breast Cancer | University Health Network, Toronto | June 23, 2016 |
| NCT03075527 | Recruiting | Mesothelioma | Dana-Farber Cancer Institute | March 9, 2017 |
| NCT02888743 | Recruiting | Microsatellite Stable, Stage IV Colorectal Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7 | National Cancer Institute (NCI) | September 5, 2016 |
| NCT03161223 | Not yet recruiting | Lymphoma, T-Cell | Columbia University | May 19, 2017 |
| NCT03377400 | Recruiting | Esophageal Squamous Cell Carcinoma | Samsung Medical Center | December 19, 2017 |
| NCT03258593 | Recruiting | Urinary Bladder Neoplasms | National Cancer Institute (NCI) | August 23, 2017 |
| NCT03011814 | Recruiting | Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | City of Hope Medical Center | January 5, 2017 |
| NCT02701400 | Recruiting | Recurrent Small Cell Lung Carcinoma | Emory University | March 8, 2016 |
| NCT02997995 | Recruiting | Breast Cancer, Estrogen Receptor Positive Tumor, Menopause, Hormone Antagonist | UNICANCER | December 20, 2016 |
| NCT03381183 | Not yet recruiting | Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma | H. Lee Moffitt Cancer Center and Research Institute | December 21, 2017 |
| NCT03158064 | Recruiting | Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma, Germinomatous Germ Cell Tumor, Dysgerminoma, Pineal Germ Cell Tumor | Memorial Sloan Kettering Cancer Center | May 17, 2017 |
| NCT03298451 | Recruiting | Hepatocellular Carcinoma | AstraZeneca | October 2, 2017 |
| NCT02537418 | Active, not recruiting | Solid Malignancies | Canadian Cancer Trials Group | September 1, 2015 |
| NCT03030131 | Recruiting | Carcinoma, Non-Small-Cell Lung | Intergroupe Francophone de Cancerologie Thoracique | January 24, 2017 |
| NCT03212807 | Not yet recruiting | EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma, Primary Testicular Lymphoma | Singapore General Hospital | July 11, 2017 |
| NCT03257761 | Recruiting | Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma | University of Southern California | August 22, 2017 |
| NCT03167619 | Not yet recruiting | Triple Negative Breast Cancer | Kimberly Blackwell | May 30, 2017 |
| NCT02870920 | Active, not recruiting | Colorectal Cancer | Canadian Cancer Trials Group | August 17, 2016 |
| NCT03519971 | Recruiting | Non-Small Cell Lung Cancer | AstraZeneca | May 9, 2018 |
| NCT03043872 | Recruiting | Small Cell Lung Carcinoma Extensive Disease | AstraZeneca | February 6, 2017 |
| NCT03319316 | Not yet recruiting | Squamous Non-small Cell Lung Cancer, Non-Squamous Non-small Cell Lung Cancer | European Organisation for Research and Treatment of Cancer - EORTC | October 24, 2017 |
| NCT02794883 | Recruiting | Malignant Glioma, Recurrent Glioblastoma | Northwestern University | June 9, 2016 |
| NCT02886065 | Active, not recruiting | Smoldering Multiple Myeloma | Massachusetts General Hospital | September 1, 2016 |
| NCT03026062 | Recruiting | Malignant Neoplasm of Female Genital Organ | M.D. Anderson Cancer Center | January 20, 2017 |
| NCT02762006 | Recruiting | Renal Cell Carcinoma, Kidney Cancer | Brian Rini | May 4, 2016 |
| NCT03089645 | Recruiting | Selected Advanced Solid Tumors | MedImmune LLC | March 24, 2017 |
| NCT02706405 | Recruiting | BCL2 Gene Rearrangement, BCL6 Gene Rearrangement, CD19 Positive, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, MYC Gene Rearrangement, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Fred Hutchinson Cancer Research Center | March 11, 2016 |
| NCT03405454 | Recruiting | Ovarian Clear Cell Carcinoma | National University Hospital, Singapore | January 23, 2018 |
| NCT03356860 | Recruiting | Breast Cancer, Triple Negative Breast Cancer, Luminal B | Grand Hôpital de Charleroi | November 29, 2017 |
| NCT03258554 | Recruiting | Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | National Cancer Institute (NCI) | August 23, 2017 |
| NCT03394144 | Recruiting | Advanced Solid Malignancies | AstraZeneca | January 9, 2018 |
| NCT03212469 | Recruiting | Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer | Gustave Roussy, Cancer Campus, Grand Paris | July 11, 2017 |
| NCT02826434 | Recruiting | Breast Cancer | Massachusetts General Hospital | July 11, 2016 |
| NCT03459846 | Recruiting | Urinary Bladder Neoplasms | AstraZeneca | March 9, 2018 |
| NCT02718911 | Recruiting | Solid Tumor | Eli Lilly and Company | March 24, 2016 |
| NCT02879617 | Recruiting | Non Small Cell Lung Cancer | Liza Villaruz, MD | August 25, 2016 |
| NCT03085225 | Recruiting | Ovarian Carcinoma, Soft Tissue Sarcoma | Institut Bergonié | March 21, 2017 |
| NCT02978482 | Active, not recruiting | Advanced Malignancy | AstraZeneca | December 1, 2016 |
| NCT03199040 | Recruiting | Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, TNBC - Triple-Negative Breast Cancer, Triple-negative Breast Carcinoma | Washington University School of Medicine | June 26, 2017 |
| NCT02764333 | Active, not recruiting | Ovarian Cancer | Memorial Sloan Kettering Cancer Center | May 6, 2016 |
| NCT02535078 | Recruiting | Malignant Melanoma | Immunocore Ltd | August 28, 2015 |
| NCT02953457 | Recruiting | BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma | Roswell Park Cancer Institute | November 2, 2016 |
| NCT03019003 | Recruiting | Head and Neck Cancer | Massachusetts General Hospital | January 12, 2017 |
| NCT03059485 | Recruiting | Acute Myelogenous Leukemia | Dana-Farber Cancer Institute | February 23, 2017 |
| NCT02866747 | Recruiting | Glioblastoma | Institut Claudius Regaud | August 15, 2016 |
| NCT02879318 | Recruiting | Pancreatic Adenocarcinoma | Canadian Cancer Trials Group | August 25, 2016 |
| NCT02318277 | Recruiting | Solid Tumors, Head and Neck Cancer, Lung Cancer, UC (Urothelial Cancer) | Incyte Corporation | December 17, 2014 |
| NCT02516241 | Recruiting | Urothelial Cancer | AstraZeneca | August 5, 2015 |
| NCT02734160 | Recruiting | Metastatic Pancreatic Cancer | Eli Lilly and Company | April 12, 2016 |
| NCT03410615 | Recruiting | Oropharyngeal Squamous Cell Carcinoma | Canadian Cancer Trials Group | January 25, 2018 |
| NCT02777710 | Recruiting | Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer, Advanced Cancer | Centre Leon Berard | May 19, 2016 |
| NCT02118337 | Recruiting | Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma | MedImmune LLC | April 21, 2014 |
| NCT02503774 | Recruiting | Solid Tumours | MedImmune LLC | July 21, 2015 |
| NCT02542293 | Recruiting | Non Small Cell Lung Carcinoma NSCLC | AstraZeneca | September 7, 2015 |
| NCT02227667 | Recruiting | Advanced Colorectal Cancer | Memorial Sloan Kettering Cancer Center | August 28, 2014 |
| NCT02583477 | Active, not recruiting | Metastatic Pancreatic Ductal Adenocarcinoma | AstraZeneca | October 22, 2015 |
| NCT02871323 | Active, not recruiting | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis | Northwestern University | August 18, 2016 |
| NCT02369874 | Active, not recruiting | Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN | AstraZeneca | February 24, 2015 |
| NCT02261220 | Active, not recruiting | Advanced Solid Tumors | MedImmune LLC | October 10, 2014 |
| NCT02551159 | Active, not recruiting | Squamous Cell Carcinoma of the Head and Neck | AstraZeneca | September 16, 2015 |
| NCT02454933 | Active, not recruiting | Locally Advanced or Metastatic EGFR T790M+ NSCLC | AstraZeneca | May 27, 2015 |
| NCT02766335 | Active, not recruiting | Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Southwest Oncology Group | May 9, 2016 |
| NCT02311361 | Recruiting | Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer | National Cancer Institute (NCI) | December 8, 2014 |
| NCT02617277 | Recruiting | Advanced Solid Tumours | AstraZeneca | November 30, 2015 |
| NCT02352948 | Active, not recruiting | Non - Small Cell Lung Cancer NSCLC | AstraZeneca | February 2, 2015 |
| NCT02519348 | Recruiting | Hepatocellular Carcinoma | MedImmune LLC | August 10, 2015 |
| NCT02549651 | Recruiting | Diffuse Large B-Cell Lymphoma | MedImmune LLC | September 15, 2015 |
| NCT02983578 | Recruiting | Malignant Neoplasm of Digestive Organs Intestinal Tract Primary, Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma | M.D. Anderson Cancer Center | December 6, 2016 |
| NCT02819596 | Recruiting | Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma | Queen Mary University of London | June 30, 2016 |
| NCT02336165 | Active, not recruiting | Glioblastoma | Ludwig Institute for Cancer Research | January 12, 2015 |
| NCT02431559 | Active, not recruiting | Ovarian Cancer | Ludwig Institute for Cancer Research | May 1, 2015 |
| NCT02685059 | Active, not recruiting | Breast Cancer | German Breast Group | February 18, 2016 |
| NCT02734004 | Active, not recruiting | Ovarian, Breast, SCLC, Gastric Cancers | AstraZeneca | April 12, 2016 |
| NCT02340975 | Recruiting | Gastric or Gastroesophageal Junction Adenocarcinoma | MedImmune LLC | January 19, 2015 |
| NCT01938612 | Active, not recruiting | Advanced Solid Tumors | AstraZeneca | September 10, 2013 |
| NCT02592551 | Recruiting | Mesothelioma | Baylor College of Medicine | October 30, 2015 |
| NCT02125461 | Active, not recruiting | Non-Small Cell Lung Cancer | AstraZeneca | April 29, 2014 |
| NCT02586987 | Active, not recruiting | Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer | AstraZeneca | October 27, 2015 |
| NCT01693562 | Active, not recruiting | Advanced Solid Tumors | MedImmune LLC | September 26, 2012 |
| NCT02088112 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | MedImmune LLC | March 14, 2014 |
| NCT02489448 | Recruiting | Breast Neoplasms | Yale University | July 3, 2015 |
| NCT01975831 | Active, not recruiting | Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma | Ludwig Institute for Cancer Research | November 5, 2013 |
| NCT02273375 | Recruiting | Non-Small Cell Lung Cancer | Canadian Cancer Trials Group | October 24, 2014 |
| NCT02117219 | Recruiting | Myelodysplastic Syndrome | MedImmune LLC | April 17, 2014 |
| NCT02401048 | Active, not recruiting | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Pharmacyclics LLC. | March 27, 2015 |
| NCT02572687 | Active, not recruiting | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | Eli Lilly and Company | October 9, 2015 |
| NCT02207530 | Active, not recruiting | Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck | AstraZeneca | August 4, 2014 |
| NCT02000947 | Active, not recruiting | NSCLC, Non-small Cell Lung Cancer, Lung Cancer | MedImmune LLC | December 4, 2013 |
| NCT02639026 | Recruiting | Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer | Abramson Cancer Center of the University of Pennsylvania | December 24, 2015 |
| NCT02319044 | Active, not recruiting | Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck | AstraZeneca | December 18, 2014 |
| NCT02221960 | Active, not recruiting | Recurrent or Metastatic Solid Tumors | MedImmune LLC | August 21, 2014 |
| NCT02499328 | Recruiting | Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck | AstraZeneca | July 16, 2015 |
| NCT02484404 | Recruiting | Lung Cancer, Breast Cancer, Ovarian Cancer, Colorectal Cancer, Prostate Cancer, Triple Negative Breast Cancer | National Cancer Institute (NCI) | June 29, 2015 |
| NCT03215095 | Recruiting | Thyroid Cancer | Memorial Sloan Kettering Cancer Center | July 12, 2017 |
| NCT03122496 | Recruiting | Metastatic Anaplastic Thyroid Cancer | Memorial Sloan Kettering Cancer Center | April 20, 2017 |
| NCT03283605 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma | Centre hospitalier de l'Université de Montréal (CHUM) | September 14, 2017 |
| NCT03148327 | Recruiting | Carcinoma, Non-Small-Cell Lung | Jonsson Comprehensive Cancer Center | May 11, 2017 |
| NCT03283943 | Not yet recruiting | Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | British Columbia Cancer Agency | September 15, 2017 |
| NCT03275597 | Recruiting | Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV | University of Wisconsin, Madison | September 7, 2017 |
| NCT03249142 | Recruiting | Ovarian Cancer | ARCAGY/ GINECO GROUP | August 15, 2017 |
| NCT02281084 | Recruiting | Myelodysplastic Syndromes | Celgene | November 3, 2014 |
| NCT02572843 | Recruiting | NSCLC Non-small Cell Lung Cancer | Swiss Group for Clinical Cancer Research | October 9, 2015 |
| NCT02527434 | Active, not recruiting | Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma | AstraZeneca | August 19, 2015 |
| NCT03101475 | Not yet recruiting | Colorectal Cancer, Liver Metastases | European Organisation for Research and Treatment of Cancer - EORTC | April 5, 2017 |
| NCT02900157 | Active, not recruiting | Advanced Solid Tumors | MedImmune LLC | September 14, 2016 |
| NCT03292250 | Recruiting | HNSCC, Head and Neck Neoplasms | Seoul National University Hospital | September 25, 2017 |
| NCT02821754 | Recruiting | Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer | National Cancer Institute (NCI) | July 4, 2016 |
| NCT03164772 | Recruiting | Metastatic Non-small Cell Lung Cancer, NSCLC | Ludwig Institute for Cancer Research | May 24, 2017 |
| NCT02546661 | Recruiting | Muscle Invasive Bladder Cancer | AstraZeneca | September 11, 2015 |
| NCT03144778 | Recruiting | Malignant Neoplasms of Oropharynx | M.D. Anderson Cancer Center | May 9, 2017 |
| NCT03334617 | Recruiting | Non-Small Cell Lung Cancer | AstraZeneca | November 7, 2017 |
| NCT03509012 | Recruiting | Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma | AstraZeneca | April 26, 2018 |
| NCT02143466 | Recruiting | Advanced Non Small Cell Lung Cancer | AstraZeneca | May 21, 2014 |
| NCT03267589 | Recruiting | Ovarian Cancer | Nordic Society for Gynaecologic Oncology | August 30, 2017 |
| NCT03518606 | Not yet recruiting | Advanced Solid Tumours, Breast Cancer, Head and Neck Cancer, Cervix Cancer, Prostate Cancer | UNICANCER | May 8, 2018 |
| NCT02705482 | Recruiting | Select Advanced Solid Tumors | MedImmune LLC | March 10, 2016 |
| NCT02815995 | Recruiting | Advanced and/or Metastatic Sarcoma | M.D. Anderson Cancer Center | June 28, 2016 |
Approved Drugs of Durvalumab**
| INN (trade name) | Therapeutic area | Dose | Strength | Route | Company | Marketing start | Market |
| Imfinzi | Locally Advanced or Metastatic Urothelial Carcinoma; Unresectable, Stage III Non-Small Cell Lung Cancer | Injection, Solution | 50 mg/mL | Intravenous | AstraZeneca UK LTD | May 1, 2017 |
|
| Imfinzi | Locally Advanced or Metastatic Urothelial Carcinoma; Locally Advanced, Unresectable Non-Small Cell Lung Cancer | Injection, Solution | 50 mg/mL | Intravenous | AstraZeneca Canada Inc. | November 20, 2017 |
|
What We Provide
Therapeutic Antibody
Durvalumab
We provide high-quality Durvalumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Durvalumab
** Information presented in the table were collected from the following websites:
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95736
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
